PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAztreonam
Azactam, Cayston(aztreonam)
Azactam, Aztreonam, Cayston, Emblaveo (aztreonam) is a small molecule pharmaceutical. Aztreonam was first approved as Azactam on 1986-12-31. It is used to treat bacterial infections, cellulitis, endometritis, intraabdominal infections, and pseudomonas infections amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections.
Download report
Favorite
BMS
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Azactam, Aztreonam, Cayston (discontinued: Azactam, Aztreonam)
Combinations
Emblaveo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aztreonam
Tradename
Company
Number
Date
Products
AZACTAMBristol Myers SquibbN-050580 RX1986-12-31
2 products, RLD, RS
CAYSTONGilead SciencesN-050814 RX2010-02-22
1 products, RLD, RS
Show 2 discontinued
Avibactam sodium
+
Aztreonam
Tradename
Company
Number
Date
Products
EMBLAVEOAbbVieN-217906 RX2025-02-07
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
azactamNew Drug Application2025-01-09
aztreonamANDA2024-06-03
caystonNew Drug Application2025-03-17
emblaveoNew Drug Application2025-02-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
respiratory tract infections—D012141J06.9
urinary tract infectionsEFO_0003103D014552N39.0
bacterial infections—D001424A49
intraabdominal infections—D059413—
pseudomonas infectionsEFO_0001076D011552A41.52
endometritisEFO_1001312D004716—
cellulitisEFO_0003035D002481L03.90
escherichia coli infectionsEFO_1001318D004927B96.20
proteus infectionsEFO_1001130D011512—
klebsiella infectionsEFO_1001353D007710—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DF: Monobactams
— J01DF01: Aztreonam
HCPCS
Code
Description
S0073
Injection, aztreonam, 500 mg
Clinical
Clinical Trials
70 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—17173229
FibrosisD005355———5911025
Cystic fibrosisD003550EFO_0000390E84—5911025
Communicable diseasesD003141——15171124
Pseudomonas infectionsD011552EFO_0001076A41.52—241512
Bacterial infectionsD001424—A492451—11
PneumoniaD011014EFO_0003106J18—131—4
Bacterial pneumoniaD018410EFO_1001272J15.9——11—2
AppendicitisD001064EFO_0007149K37———1—1
PseudomonasD011549—————1—1
Show 8 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pseudomonas aeruginosaD011550NCBITaxon_287——12—25
BronchiectasisD001987—J47—22——4
Ventilator-associated pneumoniaD053717EFO_1001865J95.851—13——3
Intraabdominal infectionsD059413———12——3
BacteremiaD016470EFO_0003033R78.81——2—13
Bacterial skin diseasesD017192———12——3
Enterobacteriaceae infectionsD004756EFO_1001313———2—13
Soft tissue infectionsD018461————3——3
Respiratory aspirationD053120EFO_1001839———1—23
Respiratory tract infectionsD012141—J06.9—12——2
Show 15 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteomyelitisD010019EFO_0003102M8611———2
Gram-negative bacterial infectionsD016905———2———2
Gastrointestinal microbiomeD000069196———1———1
Nose diseasesD009668———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Renal insufficiencyD051437—N191————1
Non-small-cell lung carcinomaD002289——1————1
Lung neoplasmsD008175—C34.901————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD007249MP_0001845—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAztreonam
INNaztreonam
Description
Aztreonam, sold under the brand name Azactam among others, is an antibiotic used primarily to treat infections caused by gram-negative bacteria such as Pseudomonas aeruginosa. This may include bone infections, endometritis, intra abdominal infections, pneumonia, urinary tract infections, and sepsis. It is given by intravenous or intramuscular injection or by inhalation.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O
Identifiers
PDB—
CAS-ID78110-38-0
RxCUI—
ChEMBL IDCHEMBL158
ChEBI ID161680
PubChem CID5742832
DrugBankDB00355
UNII IDG2B4VE5GH8 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Azactam – Elan Corporation
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 17,366 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
13,570 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use